Literature DB >> 26315609

Evaluation of Su Fu'ning Lotion's Inhibitory Effects on Bladder Cancer Cells In Vitro and In Vivo by Intravesical Instillation.

Liansheng Ren1, Xihua Yang2, Lili Zhao1, Hong Zhang3, Jing Wang1.   

Abstract

BACKGROUND: Bladder cancer is a common malignant tumor with a very high recurrence rate after surgery. Intravesical instillation can help clear up the residual tumor cells after surgery and thereby reduce the recurrence rate.
OBJECTIVE: To establish a bladder tumor transplantation animal model and to evaluate the inhibitory effects of a novel perfusate, Su Fu'ning Lotion (SFN), on bladder tumor.
METHODS: SFN was compared with several commonly used chemotherapy drugs, including mitomycin (MMC) and pirarubicin (THP) for anticancer effects on the bladder cancer cell lines T24, BTT, and BIU-87 and SFN half inhibitory concentrations (IC50) were determined after 48 hours of treatment. In addition, bladder cancer orthotopic transplantation tumor models were established in BALB/C nude mice and T739 mice, and SFN anticancer effects were assessed in vivo, with normal saline and MMC as negative and positive controls, respectively.
RESULTS: SFN, MMC, and THP were all lethal to bladder cancer cells, in vitro, with SFN and THP significantly superior to MMC. IC50 values for SFN were 13.22, 11.22, and 12.5 µg/mL on T24, BTT, and BIU-87 cells, respectively. In vivo, SFN significantly reduced the mouse bladder wet weight and prolonged the animal survival compared with controls (P < .05), suggesting that SFN significantly inhibited T24/BTT cell growth in mice.
CONCLUSION: SFN inhibited the bladder cancer cell proliferation in vitro and in vivo and significantly prolonged the survival of mice with bladder cancer xenografts, indicating that SFN could be used as a perfusate after surgery for removal of residual bladder cancers cells.
© The Author(s) 2015.

Entities:  

Keywords:  Su Fu’ning Lotion (SFN); bladder cancer; intravesical instillation; orthotopic transplantation tumor; postoperative recurrence

Mesh:

Substances:

Year:  2015        PMID: 26315609      PMCID: PMC5736078          DOI: 10.1177/1534735415596569

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  28 in total

1.  Effects of Brazilin on the phospholipase A2 activity and changes of intracellular free calcium concentration in rat platelets.

Authors:  G S Hwang; J Y Kim; T S Chang; S D Jeon; D S So; C K Moon
Journal:  Arch Pharm Res       Date:  1998-12       Impact factor: 4.946

2.  Brazilin augments cellular immunity in multiple low dose streptozotocin (MLD-STZ) induced type I diabetic mice.

Authors:  K M Yang; S D Jeon; D S So; C K Moon
Journal:  Arch Pharm Res       Date:  2000-12       Impact factor: 4.946

Review 3.  Epidemiology and risk factors of urothelial bladder cancer.

Authors:  Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan
Journal:  Eur Urol       Date:  2012-07-25       Impact factor: 20.096

4.  Lentivirus-mediated RNA interference of clusterin enhances the chemosensitivity of EJ bladder cancer cells to epirubicin in vitro.

Authors:  Jian Lu; Jun-Hang Luo; Jian Pang; Jia-Zheng Cao; Rong-Hai Wu; Zhu-Ting Tong; Wei Chen; Dan Xie
Journal:  Mol Med Rep       Date:  2012-08-03       Impact factor: 2.952

5.  Vasorelaxing effects of Caesalpinia sappan involvement of endogenous nitric oxide.

Authors:  Y W Xie; D S Ming; H X Xu; H Dong; P P But
Journal:  Life Sci       Date:  2000-09-01       Impact factor: 5.037

6.  Evaluation of tumor formation of three bladder cancer cell lines in nude mice.

Authors:  Fan Li; Zhangqun Ye; Weimin Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-04-20

Review 7.  Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results.

Authors:  J Alfred Witjes; Kees Hendricksen
Journal:  Eur Urol       Date:  2007-08-20       Impact factor: 20.096

8.  Heme oxygenase-1 mediates the inhibitory actions of brazilin in RAW264.7 macrophages stimulated with lipopolysaccharide.

Authors:  Chien-Ming Hu; Yung-Hung Liu; Khoot-Peng Cheah; Joe-Sharg Li; Carlos-Shu Kei Lam; Wen-Yu Yu; Cheuk-Sing Choy
Journal:  J Ethnopharmacol       Date:  2008-10-14       Impact factor: 4.360

9.  Intravesical therapy for transitional cell carcinoma of the bladder: the community practice.

Authors:  C Obek; S W Shelfo; H J Korman; M S Soloway
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

10.  Expression of a tumor-associated gene, LASS2, in the human bladder carcinoma cell lines BIU-87, T24, EJ and EJ-M3.

Authors:  Qinghua Zhao; Haifeng Wang; Mingying Yang; Delin Yang; Yigang Zuo; Jiansong Wang
Journal:  Exp Ther Med       Date:  2013-01-11       Impact factor: 2.447

View more
  2 in total

1.  Clinical Value Analysis of Xiaozheng Decoction Combined with Bladder Perfusion for Postoperative Treatment of Bladder Cancer and Its Effect on Serum miR-143 and miR-92a.

Authors:  Xifeng Yang; Honghong Lv; Wenjing Jiang; Jinzhi Zhang; Hong Hua
Journal:  J Healthc Eng       Date:  2022-03-24       Impact factor: 2.682

2.  Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer.

Authors:  Xihua Yang; Lili Zhao; Meiping Li; Lei Yan; Shengwan Zhang; Zhenguo Mi; Liansheng Ren; Jun Xu
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.